Valion Bio announced positive final safety data from a NIAID-funded study of its lead biologic candidate, Entolimod, conducted by the Armed Forces Radiobiology Research Institute (AFRRI). The study found no evidence of treatment-related toxicity or hematologic disruption in mice, supporting the advancement to a fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure.
Geron Corporation is discontinuing its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, although no new safety signals were observed.
MIRA Pharmaceuticals announced positive proof-of-concept results from an exploratory pilot study of its oral drug candidate SKNY-1 in a mouse model of obesity. The study showed significant weight and fat reduction without significant lean-mass loss or rapid weight regain compared to semaglutide, suggesting a differentiated metabolic mechanism beyond appetite suppression.
“What makes SKNY-1 particularly exciting is that our findings point toward a potentially differentiated metabolic approach, with encouraging signals regarding body composition and weight maintenance following treatment discontinuation. We believe these characteristics could become important advantages as we continue advancing SKNY-1, positioning it as a potentially valuable asset within our pipeline and an opportunity to participate in this significant global market.”
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
Benitec Biopharma announced positive interim Phase 1b/2a results for its gene therapy BB-301 in patients with Oculopharyngeal Muscular Dystrophy (OPMD). The data showed a 100% responder rate across both low and high dose cohorts, with the high dose group demonstrating greater relative improvements in throat emptying and swallowing capacity at the 3-month mark.
Oncolytics Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab for squamous cell anal cancer (SCAC). The study demonstrated a median duration of response of approximately 15 months, with 100% of responding patients surviving longer than one year, supporting a potential registration path in HPV-driven cancers.
60 Degrees Pharmaceuticals announced positive clinical and molecular results from the first five patients in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. All five patients (100%) reported significant clinical improvement and tested negative for Babesia on conventional PCR tests, supporting the potential efficacy of the combination therapy in immunosuppressed patients.
Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with atopic dermatitis and asthma. The data showed a 45% placebo-adjusted mean improvement in EASI scores for atopic dermatitis and rapid improvements in lung function for asthma patients, with a favorable safety profile and no observed conjunctivitis. The company plans to prioritize Phase 2b development of ATI-052 for eosinophilic esophagitis (EoE) starting in early 2027.
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.
Longeveron announced updated Phase 2b ELPIS II trial results for laromestrocel in infants with hypoplastic left heart syndrome (HLHS). While the trial missed its primary efficacy endpoint of RVEF change, additional analysis showed the secondary endpoint of major adverse cardiac events (MACE) achieved statistical significance with only 1 event in the treatment arm versus 8 in the standard of care arm (P=0.043).
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The submission is supported by Phase 2 FIGHT DMD trial data showing a statistically significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. While the FDA expressed concerns regarding the sufficiency of the data package for efficacy requirements, the company is moving forward with the submission following a pre-NDA meeting.
Aptevo Therapeutics reported clinical data from its Phase 1b RAINIER trial showing that 21% of frontline AML patients treated with mipletamig combination therapy advanced to potentially curative stem cell transplants. This transplant rate compares favorably to historical standard-of-care results (0.7% in the VIALE-A trial) for patients initially deemed unfit for intensive chemotherapy. The company expects to conclude dose optimization by year-end and initiate a Phase 2 trial in the first half of 2027.
Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met its primary endpoint with 61% of patients in the high-dose (600 mg) group achieving complete skin clearance (PASI 100) compared to 0% for placebo, supporting the planned initiation of Phase 3 trials in the first half of 2027.
Xencor announced updated Phase 1 clinical trial results for XmAb819, an ENPP3 x CD3 bispecific T-cell engager, in patients with advanced clear cell renal cell carcinoma (ccRCC). The company also provided a cash runway update, expecting current resources to fund operations into 2029, and plans to start a potential registration-enabling study for XmAb819 in 2027.
Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.
Counterparty
Lepu Biopharma Co., Ltd.
“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.
Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.
MacroGenics announced positive interim Phase 1 data for MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors. The study showed a 27% best overall response rate in heavily pretreated SCCHN patients and a manageable safety profile with no treatment-related discontinuations in that cohort. Based on these results, the company plans to initiate a front-line combination study evaluating MGC026 with pembrolizumab.
Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 IMAgINATION study results for sefaxersen in patients with IgA nephropathy. The trial met its primary endpoint, demonstrating a statistically significant 43.1% reduction in proteinuria compared to placebo at 37 weeks, with a safety profile consistent with earlier studies.
Counterparty
Roche
“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these positive data, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.
Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.
“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”
Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.
ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.
Tango Therapeutics announced updated Phase 1/2 clinical trial results for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate in patients with MTAP-deleted and RAS-mutant pancreatic cancer. The data demonstrated a 9-month progression-free survival rate of 88%, leading the company to plan a registrational Phase 3 trial in the first half of 2027.
NeOnc Technologies reported early clinical improvement in the first pediatric patient treated with its investigational intranasal NEO100 under a Compassionate Care program in Abu Dhabi. The company also announced a Memorandum of Understanding with the Department of Health – Abu Dhabi to cooperate on oncology and CNS therapeutic research.
MIRA Pharmaceuticals announced positive results from a 21-day IND-enabling preclinical proof-of-concept study of MIRA-55 for chronic inflammatory pain. The study showed MIRA-55 significantly reduced pain hypersensitivity with efficacy comparable to Celebrex and no observed tolerance, supporting a planned IND submission in Q1 2027.
Korro Bio announced positive preclinical results for KRRO-111, its RNA-editing development candidate for Alpha-1 Antitrypsin Deficiency (AATD). The studies demonstrated up to 95% mRNA editing and a 6-fold increase in total functional AAT protein, supporting a potential best-in-class profile for treating both lung and liver manifestations of the disease.
Roivant and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). The drug met its primary and all key secondary endpoints in two identical trials, demonstrating a median time to treatment failure of over 48 weeks compared to 12 weeks for placebo, and the company plans to file a supplemental New Drug Application (sNDA) in the first half of 2027.
Genprex highlighted peer-reviewed preclinical research published in Mechanisms of Ageing and Development regarding the TUSC2 gene, which is the therapeutic component of its REQORSA oncology program. The study found that TUSC2 deficiency in mice leads to mitochondrial dysfunction and protein homeostasis collapse in the brain, with human datasets showing TUSC2 expression also declines with age and Alzheimer's disease. While exploratory, the findings suggest TUSC2 plays a foundational role in brain health beyond its established role in cancer treatment.